Chemical engineering

NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO

Retrieved on: 
Monday, January 8, 2024

The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.

Key Points: 
  • The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.
  • Jeff Wolf, CEO of Nighthawk, commented, “Our rebranding to Scorpius Holdings is a testament to our successful transition and the growth of our CDMO operations.
  • The industry faces a critical shortage of clinical-scale biologic manufacturing capacity, driven by increasing demand for large molecule CDMO services.
  • Our state-of-the-art facility in San Antonio, Texas ideally positions us to address this gap in CDMO manufacturing capacity and services.

PPG appoints Peter Votruba-Drzal as vice president-elect, global sustainability; Diane Kappas to retire

Retrieved on: 
Monday, January 8, 2024

PPG (NYSE:PPG) today announced that Peter Votruba-Drzal will become vice president-elect, global sustainability, effective immediately.

Key Points: 
  • PPG (NYSE:PPG) today announced that Peter Votruba-Drzal will become vice president-elect, global sustainability, effective immediately.
  • Diane Kappas, current vice president, global sustainability has announced her intention to retire from PPG, effective July 1, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240108763264/en/
    PPG announced that Peter Votruba-Drzal will become vice president-elect, global sustainability, effective immediately.
  • The PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc.

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

Retrieved on: 
Monday, January 8, 2024

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer.

Key Points: 
  • Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer.
  • Before Janux, Tommy was the co-founder of Sitari Pharmaceuticals based upon his graduate work at Stanford University with Professor Chaitan Khosla.
  • Tommy was a key leader in the Sitari drug discovery and development program, whose successful culmination was the acquisition by GlaxoSmithKline.
  • In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.

Mesa Laboratories Appoints Mark Capone to its Board of Directors

Retrieved on: 
Monday, January 8, 2024

LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the “Board”), effective January 5, 2024.

Key Points: 
  • LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the “Board”), effective January 5, 2024.
  • Dr. John Sullivan, Ph.D., Chairman of the Board of Directors, stated: “We are pleased to welcome Mark to Mesa’s Board.
  • Mark is an accomplished life sciences executive with significant leadership and acquisitions experience spanning biopharmaceuticals, life science tools, and clinical genomics.
  • “I am honored to be joining the Board of Mesa – a high growth life sciences tools organization built around a vision to Protect the Vulnerable,” said Mark Capone.

Isolatek Announces New Chief Executive Officer

Retrieved on: 
Monday, January 8, 2024

Isolatek International (“Isolatek” or the “Company”), a market leading manufacturer and supplier of passive fireproofing technologies, announced today the appointment of Michael (“Mike”) Harvey as its new Chief Executive Officer, effective immediately.

Key Points: 
  • Isolatek International (“Isolatek” or the “Company”), a market leading manufacturer and supplier of passive fireproofing technologies, announced today the appointment of Michael (“Mike”) Harvey as its new Chief Executive Officer, effective immediately.
  • Isolatek is a portfolio company of SK Capital Partners (“SK Capital”).
  • Mike joins Isolatek from Five Star Products, where he served as Chief Executive Officer and President since 2017.
  • “We are pleased to welcome Mike to the Isolatek team,” said Randy Dearth, Board Member of Isolatek and Senior Director of SK Capital.

Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

Retrieved on: 
Friday, January 5, 2024

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer.
  • Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth.
  • View the full release here: https://www.businesswire.com/news/home/20240105333128/en/
    Adam Laponis, chief financial officer of Twist Bioscience (Photo: Business Wire)
    “Adam’s deep financial acumen and strategic planning expertise across diverse businesses make him an ideal fit for our next phase of growth,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Previously, Mr. Laponis served as vice president, finance and chief financial officer, cardiovascular care at Cardinal Health as the finance leader for the worldwide Cordis Cardiovascular business.

Immunome Appoints Phil Roberts as Chief Technical Officer

Retrieved on: 
Thursday, January 4, 2024

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer.

Key Points: 
  • Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer.
  • Mr. Roberts has over three decades of experience in product development, global manufacturing, and commercialization of novel pharmaceutical products.
  • “Immunome is delighted to add Phil to our management team as we advance our portfolio of immunotherapies, radioligand therapies, and ADCs towards clinical development,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
  • Prior to that, Mr. Roberts served as SVP, Technical Operations at Mirati Therapeutics, where he was responsible for pharmaceutical product development, manufacturing, and supply chain operations.

Gevo Announces Appointment of Katie Ellet to Board of Directors

Retrieved on: 
Wednesday, January 3, 2024

ENGLEWOOD, Colo., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) is pleased to announce that Katie Ellet has been appointed to its board of directors as of January 2, 2024.

Key Points: 
  • ENGLEWOOD, Colo., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) is pleased to announce that Katie Ellet has been appointed to its board of directors as of January 2, 2024.
  • She has held a wide variety of leadership roles in the chemical and energy fields for the last 27 years.
  • “We are honored to have Katie join our Board of Directors,” said Dr. Patrick Gruber, CEO of Gevo.
  • “I think we're at a pivotal moment in the development and implementation of renewable energy strategies on a global scale,” Ellet said.

EF Hutton Appoints David Sans as Head of Healthcare

Retrieved on: 
Wednesday, January 3, 2024

NEW YORK, NY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- EF Hutton, an investment bank headquartered in New York, today announced the appointment of David Sans, PhD, FAARM MBA, as Managing Director, Head of Healthcare, to lead the Company’s Healthcare & Life Sciences Investment Banking Team.

Key Points: 
  • NEW YORK, NY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- EF Hutton, an investment bank headquartered in New York, today announced the appointment of David Sans, PhD, FAARM MBA, as Managing Director, Head of Healthcare, to lead the Company’s Healthcare & Life Sciences Investment Banking Team.
  • David Sans, PhD, FAARM MBA, brings many years of biotech and pharma experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies.
  • “We continue to see innovation and opportunity across the healthcare continuum in biotechnology, medical devices, healthcare IT, healthcare services, and therapeutics, and are privileged to have someone of David’s caliber serve as Head of Healthcare,” said Joseph T. Rallo, Chief Executive Officer of EF Hutton.
  • He will oversee all healthcare transactions at EF Hutton, spearheading and driving a wide range of industry transactions.

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Retrieved on: 
Wednesday, January 3, 2024

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.

Key Points: 
  • ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.
  • “We are delighted to welcome Christi Shaw, Mert Aktar and David Marek, and the tremendous expertise and wise counsel they represent, to our Board of Directors,” said Buzz Heidt, Chairman of ReAlta's Board of Directors.
  • Prior to Kite, Ms. Shaw served as an executive officer of Eli Lilly and Company (Lilly), a global healthcare company, and president of Lilly Bio-Medicines.
  • Mr. Aktar is an accomplished life sciences industry executive with over twenty years of multinational experience bridging science and business in pharmaceuticals and biotechnology.